Jiangsu Nhwa Pharmaceutical Co., Ltd.

002262 · SZSE · China

Public Market Listing

002262SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Jiangsu Nhwa Pharmaceutical Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Serotonin/norepinephrine/dopamine transporter + 5-HT2A receptorSmall molecule
Major Depressive Disorder
Phase 1
Undisclosed / early pipelineSmall molecule
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$233M$23M$207M—report ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$625M$72M$251M—report ↗
2025-H1$415M$46M$247M—report ↗
2025-Q1$208M$26M$287M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$823M$95M$207M—report ↗

Jiangsu Nhwa Pharmaceutical Co., Ltd. reported revenue of $822.96M, up 3.8% YoY, R&D spend of $95.44M, up 15.1% YoY, and cash and equivalents of $207.06M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$793M$83M$194M—report ↗
2023-FY$713M$78M$304M—report ↗
2022-FY$640M$68M$220M—report ↗
2021-FY$610M$55M$252M—report ↗